Latest

07:34
【CCTC(06951.HK) will spend CNY 159.56 million to repurchase 1.29 million shares on Aug 6, 2026】CCTC(06951.HK) will spend CNY 159.56 million to repurchase 1.29 million shares on Aug 6, 2026 .
Tag： CCTC06951.HK
22:07
【DRAGON MINING (01712.HK): New Holding Company Lung Kam Resources to List on HKEX Main Board by Introduction; Dragon Mining to Withdraw Listing】NewTimeSpace News: DRAGON MINING announced that its wholly-owned subsidiary Lung Kam Resources will list on the HKEX Main Board by way of introduction, with each scheme share exchanged for one New Holding Company share and the Company's listing withdrawn upon completion; dealings in the New Holding Company shares are expected to commence on 2 September 2026 under the existing code 1712 with the short name "Dragon Mining" and a board lot of 1,000 shares; the scheme remains subject to court approval.
Tag： DRAGON MINING01712.HKProduct Launch
21:55
【TRANSTHERA-B (02617.HK): Class 1 New Drug Jientai (Tiengotinib Tablets) Receives Conditional NMPA Approval for FGFR2 Fusion Advanced Cholangiocarcinoma】NewTimeSpace News: TRANSTHERA-B announced that its self-developed Class 1 new drug Jientai (tiengotinib tablets) has received conditional NMPA approval for marketing, for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements in patients previously treated with systemic therapy and FGFR inhibitors; the Phase II pivotal study showed an ORR of 28.0% and median overall survival of 20.7 months; the drug has received US FDA Orphan Drug Designation and Fast Track Designation and European EMA Orphan Drug Designation, and this is its first indication approved in China.
Tag： TRANSTHERA-B02617.HKNMPA Approval
21:47
【TOP EDUCATION (01752.HK): Acknowledges Potential Data Security Incident, Launches Investigation and Notifies Regulators】NewTimeSpace News: TOP EDUCATION announced that on 5 August it became aware of a threat actor claiming to possess and intend to sell records allegedly relating to students on an underground forum; the Group has immediately launched an investigation and notified the Tertiary Education Quality and Standards Agency and the Australian Cyber Security Centre; the suspected incident has not caused material disruption to the Group's operations to date, and the Group will take appropriate actions as the investigation progresses.
Tag： TOP EDUCATION01752.HKnetwork security
21:34
【HENGRUI PHARMA (01276.HK): Trastuzumab Rezetecan Approved for Third Indication, Becoming China's First Anti-HER2 Product Approved for Colorectal Cancer】NewTimeSpace News: HENGRUI PHARMA announced that the third indication of its subsidiary Suzhou Shengdiya's trastuzumab rezetecan for injection has been approved for marketing, for adult patients with HER2-positive colorectal cancer who failed oxaliplatin, fluorouracil and irinotecan, making it the first anti-HER2 product approved for colorectal cancer in China; the self-developed HER2 ADC has its pivotal Phase III data presented at the 2026 ASCO Annual Meeting, 11 indications included in the Breakthrough Therapy Designation list, and cumulative R&D investment of approximately RMB 2.144 billion.
Tag： HENGRUI PHARMA01276.HKIndications approved
21:28
【HENGRUI PHARMA (01276.HK): Class 1 Innovative Drug Ivarmacitinib Sulfate Tablets Approved for Fifth Indication, Completing Full-Disease-Spectrum Coverage of Axial Spondyloarthritis】NewTimeSpace News: HENGRUI PHARMA announced that the NMPA has approved a fifth indication for its self-developed Class 1 innovative drug ivarmacitinib sulfate tablets, for adult patients with active non-radiographic axial spondyloarthritis, achieving full-disease-spectrum oral targeted management coverage of axial spondyloarthritis; the product is a highly selective JAK1 inhibitor with pivotal Phase III data presented at the 2026 EULAR Annual Meeting, and cumulative R&D investment of approximately RMB 1.235 billion.
Tag： HENGRUI PHARMA01276.HKbiopharmaceutical
21:17
【ENVISION GREEN (01783.HK): Subsidiary to Purchase High-Performance Servers for RMB 1.2884 Billion, Constituting a Major Transaction】NewTimeSpace News: ENVISION GREEN announced that its indirect wholly-owned subsidiary Shanghai Youfu Cloud Computing intends to purchase high-performance servers for RMB 1.2884 billion (approximately HKD 1.4885 billion, inclusive of tax) from Shanghai Shunquan Technology to support the Group's cloud computing and intelligent computing capabilities; as the applicable percentage ratios exceed 25% but are below 100%, the transaction constitutes a major transaction; written approval from shareholders holding approximately 50.62% has been obtained, and no general meeting will be convened.
Tag： ENVISION GREEN01783.HKBusiness Updates
20:03
【NETJOY (02131.HK): Independent Internal Control Follow-up Review Completed with All Remedial Measures Implemented; Trading Suspension Continues】NewTimeSpace News: NETJOY announced that its independent internal control follow-up review has been completed; all remedial measures recommended in the internal control review report have been implemented and are operating, except for procurement acceptance processes (not applicable as the Group ended its new short-drama purchase business in June) and inventory transfers (no samples available as the Group operates a single warehouse), with the Board affirming the rectification results; the Company's shares have been suspended since 1 April 2025 and will remain suspended until all resumption guidance is met.
Tag： Netjoy02131.HKinternal control review
19:50
【Sichuan Biokin Pharmaceutical Files for Hong Kong IPO: Yizekang Becomes World's First Approved Bispecific ADC with 15 Clinical-Stage Pipeline Candidates】NewTimeSpace News: Sichuan Biokin Pharmaceutical filed for a Hong Kong IPO on 6 August with CITIC Securities, Jefferies, CICC and Deutsche Bank as joint sponsors; the integrated biopharmaceutical group has 15 clinical-stage candidates, five of which are in overseas clinical development; core product Yizekang is the world's first approved bispecific ADC with NDAs approved by the NMPA for nasopharyngeal carcinoma and esophageal squamous cell carcinoma, while T-Bren is a HER2 ADC with best-in-class potential.
Tag： Biokin PharmaIPOfile a listing application
19:35
【PACIFIC BASIN(02343.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 105.05 million, YoY increase of 310.35%】NewTimeSpace News: August 06, 2026, PACIFIC BASIN(02343.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.11 billion, increased by 8.52% YoY.
Tag： PACIFIC BASIN02343.HKprofit growth
19:33
【TOM GROUP(02383.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of HKD 157.44 million, loss widened by 59.51% YoY】NewTimeSpace News: August 06, 2026, TOM GROUP(02383.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 335.25 million, decreased by 1.02% YoY.
Tag： TOM GROUP02383.HKLoss widens
19:31
【CITIC SEC (06030.HK): Placement of Approximately 803.7 Million New H Shares to CITIC Financial Holdings Completed, Net Proceeds of Approximately HKD 18.413 Billion】NewTimeSpace News: CITIC SEC announced the completion of the issue of 803,725,383 new H shares to CITIC Financial Holdings on 6 August 2026 at an issue price of HKD 23.13 per share, with total proceeds of RMB 16 billion and net proceeds of approximately HKD 18.413 billion; following completion, CITIC Financial Holdings holds approximately 23.96% of the Company, with the new H shares subject to a 48-month lock-up; all net proceeds will be retained overseas for international business development, including capital injection of up to RMB 16 billion into CITIC Securities International.
Tag： CITIC SEC06030.HKH-share issuance
19:28
【HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia】NewTimeSpace News: HANSOH PHARMA announced that HS-10582 tablets, a Class 1 new drug independently developed by the Group, has received the Drug Clinical Trial Approval Notice from the NMPA, intended for clinical trials for the treatment of primary hypercholesterolemia and mixed dyslipidemia in adults, marking new progress in its R&D.
Tag： HANSOH PHARMA03692.HKClinical Trial
18:40
【HAOHAI BIOTEC (06826.HK): Subsidiary's Trifocal Toric IOL Obtains Medical Device Registration Certificate, Becoming First Domestically Approved Trifocal Toric IOL in China】NewTimeSpace News: HAOHAI BIOTEC announced that its controlling subsidiary Saimaishi has obtained an NMPA medical device registration certificate for its trifocal toric IOL (valid until 3 August 2031), which passed the special review procedure for innovative medical devices and is the first domestically approved trifocal toric IOL in China; the Company has formed a high-end refractive IOL product matrix covering monofocal through multifocal toric correction; as the product has not yet generated sales, it will not materially affect near-term results.
Tag： HAOHAI BIOTEC06826.HKdrug registration application
18:26
【TRIUMPH NEW EN (01108.HK): Receives Regulatory Warning Letter from CSRC Henan Bureau over Untimely Disclosure of Litigation and Arbitration; Chairman and Two Senior Executives Held Primarily Responsible】NewTimeSpace News: TRIUMPH NEW EN announced that it has received a regulatory warning letter from the CSRC Henan Bureau for untimely disclosure, as cumulative litigation and arbitration over 12 months reached RMB 333 million (10.73% of the absolute value of the latest audited net assets); Chairman Mr. Xie Jun, General Manager Mr. Chen Peng and Board Secretary Mr. Chen Hongzhao were held primarily responsible for failing to perform duties diligently; the Company must submit a written rectification report within 15 working days.
Tag： TRIUMPH NEW EN01108.HKadministrative supervision and management
18:18
【C FIN SERVICES (00605.HK): Subsidiary Grants Loan of RMB 8.3 Million at Annual Interest Rate of 12%】NewTimeSpace News: C FIN SERVICES announced that its wholly-owned subsidiary Shenzhen Lingda Small Loans granted a loan of RMB 8.3 million with a six-month term to Customer GL at an annual interest rate of 12%, secured by a residential property mortgage in Nanshan, Shenzhen (valued at approximately RMB 10.461 million); as the applicable percentage ratio exceeds 5% but is below 25%, the loan constitutes a discloseable transaction.
Tag： C FIN SERVICES00605.HKloan
18:14
【MEDIA CHINESE (00685.HK): Discloseable Transaction for Disposal of Canada Property Completed on 6 August】NewTimeSpace News: MEDIA CHINESE(00685.HK) announced the completion of the proposed disposal of a property in Canada on 6 August 2026; upon completion, the vendor is no longer the owner of the property; the disposal constitutes a discloseable transaction.
Tag： MEDIA CHINESE00685.HKSale
18:11
【HK Stock Connect Daily Report: HK Stock Connect list adjustment takes effect, MINIMAX surges 17% against the trend on its first day of admission - 20260806】On 6 August, the three major Hong Kong indices opened lower and declined throughout the day, with the Hang Seng Index down 1.49% to 25,530.28 points, the Hang Seng TECH Index down 2.28% and turnover of HKD 255.2 billion. On the trading front, the "twin titans" of large models strengthened against the trend, with MINIMAX-W (00100) surging 17.1% on its first day of formal admission to the connect and Z.AI (02513) up 4.42%; coal stocks led the gains, with YANKUANG ENERGY up 6.12%; gold stocks were active, with LINGBAO GOLD up 4.82%. Hong Kong insurance stocks were weak throughout the day, with AIA down 5.92%, dragged by rumors of taxation on gains from offshore policies. Southbound capital saw a net sell of HKD 1.461 billion. The HK Stock Connect list was adjusted today, with MINIMAX, Luxshare ICT and CCTC formally admitted.
Tag： HK Stock Connect Daily ReportSMICREALORD TECHMINIMAX-W
17:54
【Linmon Media Limited (09857.HK): Expected H1 Net Profit to Surge Around 77.7% to 255.4% Year-on-Year】NewTimeSpace News: Linmon Media Limited announced on 6 August that it expects net profit, net profit attributable to owners and adjusted net profit for the six months ended 30 June 2026 to range from approximately RMB20 million to RMB40 million.
Tag： Linmon Media Limited09857.HK
17:53
【S HARBOURHOLD (01663.HK): Chairman and Major Shareholder Wang Linbing Increases Shareholding by 9,446,000 Shares at Average Price of Approximately HKD 0.052 Per Share】NewTimeSpace News: S HARBOURHOLD(01663.HK) announced that chairman and major shareholder Mr. Wang Linbing purchased 9,446,000 ordinary shares of the Company in the open market on 6 August 2026, at an average price of approximately HKD 0.052 per share and a highest price of HKD 0.055 per share; Mr. Wang is the husband of major shareholder Ms. Chen Xiangling and the father of executive director Mr. Wang Lei.
Tag： S HARBOURHOLD01663.HKShare Increase
Previous1..107108 109110111..484     484 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments